Is the ongoing use of placebo in relapse-prevention clinical trials in schizophrenia justified?

In the absence of such studies it is risky to assume that patients are not at risk of significant distress and long-term harm, and therefore it is difficult to justify the ongoing use of placebo in relapse-prevention RCTs in schizophrenia.